filmov
tv
aml
0:02:07
The importance of induction chemotherapy in the AML treatment
0:18:29
AML Treatment Challenges Who, When, and How
0:03:25
Treatment approaches for elderly/unfit patients with AML ineligible for intensive chemotherapy
0:03:35
AML einfach erklärt ❕ Was ist Akute Myeloische Leukämie? (Experte erklärt)
0:02:31
Updates in the diagnosis, risk stratification & treatment of AML: WHO, ICC, and ELN classifications
0:02:30
Molecular Testing for Newly Diagnosed AML
0:01:39
The significance of FLT3 mutations in AML
1:14:27
Major Treatment Decisions for Patients with Acute Myeloid Leukemia (AML)
0:00:56
What causes AML?
0:01:40
Outcomes & treatment options for patients with AML who relapse after alloHSCT
0:01:39
How can MRD guide treatment of AML?
0:01:46
The challenges facing elderly AML treatment
0:02:38
Managing the progression of MDS to AML
0:01:03
What is secondary acute myeloid leukemia, or secondary AML?
0:04:30
Significance of FLT3 Mutations in AML
0:02:03
Maintenance therapy in AML
0:01:32
Novel treatment combinations for FLT3-mutated AML
0:02:52
Diagnosis, Transplant, and Hospitalization: Acute Myeloid Leukemia (AML)
0:02:11
Future prospects for CAR-T cell therapy in AML
0:02:36
Julie Abell's Acute Myeloid Leukaemia (AML) story
0:13:10
Acute Leukemia - ALL and AML - Hematology and Oncology Series
0:03:34
Treating patients with AML who are ineligible for intensive chemotherapy
0:05:42
Treating AML in patients over 70
0:01:09
Pre-MEASURE: patients with AML in complete remission but high risk of relapse following alloHCT
Назад
Вперёд
0:02:07
0:18:29
0:03:25
0:03:35
0:02:31
0:02:30
0:01:39
1:14:27
0:00:56
0:01:40
0:01:39
0:01:46
0:02:38
0:01:03
0:04:30
0:02:03
0:01:32
0:02:52
0:02:11
0:02:36
0:13:10
0:03:34
0:05:42
0:01:09